Volume | 203,456 |
|
|||||
News | - | ||||||
Day High | 188.47 | Low High |
|||||
Day Low | 185.095 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Penumbra Inc | PEN | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
187.47 | 185.095 | 188.47 | 187.78 | 188.00 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
6,607 | 203,456 | US$ 187.46 | US$ 38,139,896 | - | 180.93 - 348.67 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:00:00 | 29,578 | US$ 187.78 | USD |
Penumbra Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
7.27B | 38.70M | - | 1.06B | 90.95M | 2.35 | 79.88 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Penumbra News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PEN Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 191.71 | 198.48 | 184.10 | 189.25 | 403,335 | -3.93 | -2.05% |
1 Month | 201.50 | 204.12 | 184.10 | 191.89 | 314,175 | -13.72 | -6.81% |
3 Months | 227.47 | 228.76 | 184.10 | 205.65 | 342,246 | -39.69 | -17.45% |
6 Months | 244.77 | 277.34 | 184.10 | 227.53 | 339,299 | -56.99 | -23.28% |
1 Year | 334.89 | 348.67 | 180.93 | 241.84 | 373,156 | -147.11 | -43.93% |
3 Years | 291.10 | 348.67 | 114.865 | 227.47 | 311,642 | -103.32 | -35.49% |
5 Years | 163.60 | 348.67 | 107.50 | 212.24 | 357,811 | 24.18 | 14.78% |
Penumbra Description
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for the neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States. |